Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
May 04, 2021 08:00 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose...
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
April 19, 2021 08:00 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT), a clinical stage biopharmaceutical company dedicated to advancing targeted...
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
March 22, 2021 08:00 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (Nasdaq: RZLT) today presented positive results of a Phase 2a study of RZ358 in patients with...
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
March 08, 2021 08:00 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced the appointments of Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA to its...
Rezolute to Participate in Upcoming Investor Conferences in March
March 02, 2021 17:16 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company’s CEO and Founder, will be presenting at the following...
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
February 10, 2021 16:05 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020. Recent Business Highlights ...
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
January 12, 2021 08:30 ET
|
Rezolute Inc.
RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME Trial initiation marks expansion of the Company’s pipeline to a second clinical-stage...
Rezolute Announces Change of Transfer Agent
December 28, 2020 16:05 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the...
FDA Clears Rezolute’s IND Application for RZ402
December 03, 2020 08:00 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today that the U.S....
Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 19, 2020 08:00 ET
|
Rezolute Inc.
REDWOOD CITY, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and...